BridgeBio Pharma, Inc. — Director's Dealing 2024

Dec 28, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2024-12-24

Reporting Person: Kumar Neil (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-12-24	Common Stock	G	4685725	—	Disposed	211718	Direct
2024-12-24	Common Stock	G	4685725	—	Acquired	5698447	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	995686	Indirect

Footnotes

F1: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.